Adverse reactions to immunotherapy are associated with different patterns of sensitization to grass allergens

Sastre, Joaquı́n; Rodríguez, F.; Campo, Paloma; Laffond, Elena; Marín, Alicia; Alonso, María Dolores

doi:10.1111/all.12575

Cited by 39 publications

(29 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, a recent study conducted in Italy showed that 23% of pollen-sensitized patients had IgE antibodies to profilins [27] and frequent sensitization to cross-reactive pollen allergens has been reported for many countries such as the southern parts of Europe [7,21,28,29]. In fact, patients in Astana, Kazakhstan, are exposed simultaneously to pollen from several unrelated plant species due to a short summer period with copollination of trees, grasses, and weeds.…”

Section: Discussionmentioning

confidence: 99%

Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure

Saltabayeva¹,

Garib²,

Morenko³

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Allergen molecule-based diagnosis has been suggested to facilitate the identification of disease-causing allergen sources and the prescription of allergen-specific immunotherapy (AIT). The aim of the current study was to compare allergen molecule-based IgE serology with allergen extract-based skin testing for the identification of the disease-causing allergen sources. The study was conducted in an area where patients are exposed to pollen from multiple sources (trees, grasses, and weeds) at the same time to compare the diagnostic efficiency of the 2 forms of diagnosis. Methods: Patients from Astana, Kazakhstan, who suffered from pollen-induced allergy (n = 95) were subjected to skin prick testing (SPT) with a local panel of tree pollen, grass pollen, and weed pollen allergen extracts and IgE antibodies specific for marker allergen molecules (nArt v 1, nArt v 3, rAmb a 1, rPhl p 1, rPhl p 5, rBet v 1) were measured by ImmunoCAP. Direct and indirect costs for diagnosis based on SPT and marker allergen-based IgE serology as well as direct costs for immunotherapy depending on SPT and serological test results were calculated. Results: The costs for SPT-based diagnosis per patient were lower than the costs for allergen molecule-based IgE serology. However, allergen molecule-based serology was more precise in detecting the disease-causing allergen sources. A lower number of immunotherapy treatments (n = 119) was needed according to molecular diagnosis as compared to extract-based diagnosis (n = 275), which considerably reduced the total costs for diagnosis and for a 3-year treatment from EUR 1,112.30 to 521.77 per patient. Conclusions: The results from this real-life study show that SPT is less expensive than allergen molecule-based diagnostic testing, but molecular diagnosis allowed more precise prescription of immunotherapy which substantially reduced treatment costs and combined costs for diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure

Saltabayeva¹,

Garib²,

Morenko³

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…In an allergen study involving subcutaneous immunotherapy with an accelerated schedule, profilin-sensitized patients showed higher specific IgE levels to major grass allergens and a higher probability of suffering from systemic side effects, particularly late-phase urticarial reactions [6]. All of these findings support the idea that profilin sensitization and profilin hypersensitivity prevalence in a particular area have the potential to predict the allergic inflammation level associated with grass pollinosis.…”

mentioning

confidence: 72%

Could Profilin Be a ‘Canary in a Coal Mine' of the Increasing Allergy Epidemic?

Barber¹

2015

Int Arch Allergy Immunol

View full text Add to dashboard Cite

“…The molecular-based diagnosis would certainly improve the accuracy in AIT prescription [22, 123, 124], allowing to dissect the genuine sensitizations and the cross-reactions due to pan-allergens. The epicutaneous and intralymphatic routes of administration would represent an intriguing prospective approach, especially in the pediatric age [27].…”

Section: The Unmet Needs and The Future Directionsmentioning

confidence: 99%

Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report

et al. 2017

View full text Add to dashboard Cite

Allergen-specific immunotherapy (AIT) is currently recognized as a clinically effective treatment for allergic diseases, with a unique disease-modifying effect. AIT was introduced in clinical practice one century ago, and performed in the early years with allergenic extracts of poor quality and definition. After the mechanism of allergic reaction were recognized, the practice of AIT was refined, leading to remarkable improvement in the efficacy and safety profile of the treatment. Currently AIT is accepted and routinely prescribed worldwide for respiratory allergies and hymenoptera venom allergy. Both the subcutaneous (SCIT) and sublingual (SLIT) routes of administration are used in the pediatric population.AIT is recommended in allergic rhinitis/conjunctivitis with/without allergic asthma, with an evidence of specific IgE-sensitization towards clinically relevant inhalant allergens. Long-term studies provided evidence that AIT can also prevent the onset of asthma and of new sensitizations. The favorable response to AIT is strictly linked to adherence to treatment, that lasts 3–5 years. Therefore, several factors should be carefully evaluated before starting this intervention, including the severity of symptoms, pharmacotherapy requirements and children and caregivers’ preference and compliance.In recent years, there have been increasing interest in the role of AIT for the treatment of IgE-associated food allergy and extrinsic atopic dermatitis. A growing body of evidence shows that oral immunotherapy represents a promising treatment option for IgE-associated food allergy. On the contrary, there are still controversies on the effectiveness of AIT for patients with atopic dermatitis.This consensus document was promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP) to provide evidence-based recommendations on AIT in order to implement and optimize current prescription practices of this treatment for allergic children.

show abstract

Adverse reactions to immunotherapy are associated with different patterns of sensitization to grass allergens

Cited by 39 publications

References 11 publications

Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure

Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure

Could Profilin Be a ‘Canary in a Coal Mine' of the Increasing Allergy Epidemic?

Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report

Contact Info

Product

Resources

About